Roth Capital Issues Positive Estimate for TLSI Earnings

Key Points

• Roth Capital has improved its earnings outlook for TriSalus Life Sciences, raising the Q3 2025 earnings per share estimate from ($0.12) to ($0.10).
• TLSI stock opened at $4.55 and has a market capitalization of $172.17 million, with a P/E ratio of -3.86.
• TriSalus Life Sciences reported Q2 earnings of ($0.27) per share, missing expectations, but its revenue of $11.21 million exceeded analyst estimates.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Investment analysts at Roth Capital lifted their Q3 2025 EPS estimates for TriSalus Life Sciences in a research note issued on Wednesday, August 13th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.10) per share for the quarter, up from their previous forecast of ($0.12). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share. Roth Capital also issued estimates for TriSalus Life Sciences' Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.01 EPS.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The firm had revenue of $11.21 million for the quarter, compared to analysts' expectations of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences Stock Performance

Shares of TLSI traded up $0.03 during mid-day trading on Monday, hitting $5.15. 43,377 shares of the company traded hands, compared to its average volume of 62,886. The stock has a market cap of $194.88 million, a price-to-earnings ratio of -4.36 and a beta of 0.48. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $5.88. The stock has a 50-day moving average price of $4.75 and a two-hundred day moving average price of $5.20.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds have recently bought and sold shares of TLSI. Police & Firemen s Retirement System of New Jersey purchased a new stake in TriSalus Life Sciences during the second quarter valued at approximately $29,000. JPMorgan Chase & Co. increased its holdings in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock valued at $41,000 after buying an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in TriSalus Life Sciences during the second quarter valued at approximately $47,000. Charles Schwab Investment Management Inc. purchased a new stake in TriSalus Life Sciences during the first quarter valued at approximately $55,000. Finally, Renaissance Technologies LLC purchased a new stake in TriSalus Life Sciences during the fourth quarter valued at approximately $67,000. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.